Pfizer Announces Opening of New China Research and Development Center in Shanghai
Share :  
  • Shanghai    October 31, 2005

  • Pfizer announced the official opening of a new Research and Development Center in Shanghai. The state-of-the-art facility will provide drug development support capabilities and biometric expertise to China and the Asian region. Ms. Karen Katen, Vice Chairman of Pfizer Inc and President, Pfizer Human Health has been present the opening ceremony of the R&D center as the special guest. During her Shanghai trip, Ms. Karen also delivered her advice on Pfizer's support to the Shanghai community healthcare service at the 17th session of Shanghai IBLAC (International Business Leaders' Advisory Council).

    The Pfizer China Research and Development Center will provide input to study design, data management and statistical analysis for global clinical trials. It is during the clinical trial phases of research that potential new medicines are studied in people to determine their safety and efficacy. Additionally, the center will provide support for training in internationally-recognized Good Clinical Practice standards to Pfizer colleagues in China as well as other Pfizer operations in Asia.

    "China is an important market for Pfizer and it offers a large number of highly skilled and talented scientists," said Dr. Joseph Feczko, Pfizer's Chief Medical Officer. "The Research and Development Center we're setting up in Shanghai is not only an investment to expand Pfizer's R&D capability, it is also an investment in China's knowledge based industry and infrastructure. Pfizer's planned investment into this R&D center will near US$25 million over the next 5 years", Feczko added.

    Pfizer said the establishment of this research facility was based upon a successful pilot program initiated recently. The decision to expand this program into a world class research facility will make China an integral component of Pfizer's worldwide US$ 7.9 billion pharmaceutical development program.

    With the establishment of the R&D center, Pfizer plans to initiate collaborations with Chinese partners to develop the capabilities and talents of local scientists, biostatisticians, medical professionals, pharmacists and others with expertise in the life sciences. The global healthcare company plans to assist in the development of an environment that will nurture research and innovative drug development in China.

    "Pfizer is committed to China, both in terms of serving the broader health care needs of its patients as well as advancing the country's scientific and research capabilities. This is evidenced by the establishment of the research and development center in Shanghai as well as our goal to introduce some 20 new medications to China by 2010", said Mr. Allan Gabor, Chairman and General Manager of Pfizer China.

Text SizeAAA